WO2011035416A1 - Composés modulateurs de la hsp90, compositions, procédés et utilisations correspondants - Google Patents

Composés modulateurs de la hsp90, compositions, procédés et utilisations correspondants Download PDF

Info

Publication number
WO2011035416A1
WO2011035416A1 PCT/CA2010/001481 CA2010001481W WO2011035416A1 WO 2011035416 A1 WO2011035416 A1 WO 2011035416A1 CA 2010001481 W CA2010001481 W CA 2010001481W WO 2011035416 A1 WO2011035416 A1 WO 2011035416A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
disease
mmol
heterocyclyl
hydrogen
Prior art date
Application number
PCT/CA2010/001481
Other languages
English (en)
Inventor
Irina Denissova
Jean-Hugues Fournier
James B . Jaquith
Alain Laurent
Yannick Rose
Melanie Proulx
Original Assignee
Aegera Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aegera Therapeutics Inc. filed Critical Aegera Therapeutics Inc.
Publication of WO2011035416A1 publication Critical patent/WO2011035416A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

L'invention porte sur des composés thérapeutiques qui se fixent à la HSP90, lesdits composés contenant un groupe benzamide lié à un système tricyclique de noyaux condensés par l'atome d'azote d'un pyrrole situé au centre du système condensé. Les composés de la présente invention se fixent à la HSP90 et modifient l'aptitude à chaperonner des protéines HSP90. L'invention porte également sur des composés de benzonitrile intermédiaires qui sont des précurseurs pour les composés de benzamide. L'invention porte également sur des compositions pharmaceutiques comprenant ces composés et sur des procédés de traitement de maladies et de troubles tels qu'un cancer, des maladies auto-immunes et d'autres maladies.
PCT/CA2010/001481 2009-09-25 2010-09-24 Composés modulateurs de la hsp90, compositions, procédés et utilisations correspondants WO2011035416A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24595109P 2009-09-25 2009-09-25
US61/245,951 2009-09-25
US37148210P 2010-08-06 2010-08-06
US61/371,482 2010-08-06

Publications (1)

Publication Number Publication Date
WO2011035416A1 true WO2011035416A1 (fr) 2011-03-31

Family

ID=43795249

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2010/001481 WO2011035416A1 (fr) 2009-09-25 2010-09-24 Composés modulateurs de la hsp90, compositions, procédés et utilisations correspondants

Country Status (1)

Country Link
WO (1) WO2011035416A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9624195B2 (en) 2014-12-24 2017-04-18 Gilead Sciences, Inc. Isoquinoline compounds
US9701677B2 (en) 2014-12-24 2017-07-11 Gilead Sciences, Inc. Fused pyrimidine compounds
US9730936B2 (en) 2014-12-24 2017-08-15 Gilead Sciences, Inc. Quinazoline compounds
WO2018081814A1 (fr) * 2016-10-31 2018-05-03 University Of Kansas Inhibiteurs sélectifs de grp94 et leurs utilisations
CN108218897A (zh) * 2018-03-02 2018-06-29 湘潭大学 多取代硒吩并吲哚及衍生物及其合成方法
WO2023077216A1 (fr) * 2021-11-02 2023-05-11 Bright Angel Therapeutics Inc. Inhibiteurs de la protéine de choc thermique 90 (hsp90) pour le traitement d'infections fongiques et leurs procédés d'utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133634A1 (fr) * 2005-06-14 2006-12-21 Beijing Gylongly Biodemtech Co., Ltd Dérivés tétrahydroindole et dérivés tétrahydroindazole et leur utilisation
CA2619362A1 (fr) * 2005-08-19 2007-03-01 Schering Corporation Antagonistes mglur1 tricycliques fusionnes utilises en tant qu'agents therapeutiques
CA2619419A1 (fr) * 2005-08-19 2007-03-22 Schering Corporation Antagonistes tricycliques fusionnes du recepteur metabotropique du glutamate (mglur), en tant qu'agents therapeutiques
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133634A1 (fr) * 2005-06-14 2006-12-21 Beijing Gylongly Biodemtech Co., Ltd Dérivés tétrahydroindole et dérivés tétrahydroindazole et leur utilisation
CA2619362A1 (fr) * 2005-08-19 2007-03-01 Schering Corporation Antagonistes mglur1 tricycliques fusionnes utilises en tant qu'agents therapeutiques
CA2619419A1 (fr) * 2005-08-19 2007-03-22 Schering Corporation Antagonistes tricycliques fusionnes du recepteur metabotropique du glutamate (mglur), en tant qu'agents therapeutiques
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9624195B2 (en) 2014-12-24 2017-04-18 Gilead Sciences, Inc. Isoquinoline compounds
US9701677B2 (en) 2014-12-24 2017-07-11 Gilead Sciences, Inc. Fused pyrimidine compounds
US9730936B2 (en) 2014-12-24 2017-08-15 Gilead Sciences, Inc. Quinazoline compounds
US10206926B2 (en) 2014-12-24 2019-02-19 Gilead Sciences, Inc. Quinazoline compounds
US10548898B2 (en) 2014-12-24 2020-02-04 Gilead Sciences Inc. Quinazoline compounds
US11304948B2 (en) 2014-12-24 2022-04-19 Gilead Sciences, Inc. Quinazoline compounds
WO2018081814A1 (fr) * 2016-10-31 2018-05-03 University Of Kansas Inhibiteurs sélectifs de grp94 et leurs utilisations
US10975030B2 (en) 2016-10-31 2021-04-13 University Of Kansas Grp94 selective inhibitors and uses thereof
US11939291B2 (en) 2016-10-31 2024-03-26 University Of Kansas GRP94 selective inhibitors and uses thereof
CN108218897A (zh) * 2018-03-02 2018-06-29 湘潭大学 多取代硒吩并吲哚及衍生物及其合成方法
CN108218897B (zh) * 2018-03-02 2020-12-11 湘潭大学 多取代硒吩并吲哚及衍生物及其合成方法
WO2023077216A1 (fr) * 2021-11-02 2023-05-11 Bright Angel Therapeutics Inc. Inhibiteurs de la protéine de choc thermique 90 (hsp90) pour le traitement d'infections fongiques et leurs procédés d'utilisation

Similar Documents

Publication Publication Date Title
AU2003235741B2 (en) Deazapurines and uses thereof
WO2011035416A1 (fr) Composés modulateurs de la hsp90, compositions, procédés et utilisations correspondants
CA2760174A1 (fr) Inhibiteurs de proteines kinases et leurs utilisations
US20200385369A1 (en) New benzimidazoles derivatives as tec kinases family inhibitors
CA2939286A1 (fr) Spirocyclique contenant des composes et usages pharmaceutiques dudit spirocyclique
CA2808432A1 (fr) Composes ameliorant l'activite de proteasome tricyclique au moyen d'une ame thieno[2,3-d]pyrimidine
JP6574289B2 (ja) 多発性硬化症を治療するためのレチノイン酸関連核内オーファン受容体拮抗剤である置換された２，３−ジヒドロ−１ｈ−インデン−１−オン
US11471446B2 (en) Compounds for treatment of hypoproliferative disorders
AU2003292320A1 (en) Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same
JP5204227B2 (ja) ベンゼンスルホニル−クロマン、チオクロマン、テトラヒドロナフタレン、および関連するガンマセクレターゼインヒビター
EP1315732A2 (fr) Radicicol et monocillin et leurs analogues et leurs utilisations
JP2016537367A (ja) プロテインキナーゼ阻害剤
WO2011035417A1 (fr) Composés se fixant à la hsp-90, compositions de ceux-ci et leur utilisation dans le traitement de maladies auto-immunes et inflammatoires
JPWO2020032105A1 (ja) 光学活性な架橋型ピペリジン誘導体
TW201625641A (zh) Ｎａｍｐｔ抑制劑及方法
JP2017503006A (ja) プロテインキナーゼ阻害剤
US9822120B2 (en) Protein kinase inhibitors
JP2021134218A (ja) 光学活性なアザビシクロ環誘導体からなる医薬
JPH11152274A (ja) 新規ピリダジン誘導体及びこれを有効成分とする医薬
US20200215036A1 (en) Benzimidazole compounds as kinase inhibitors
CN117447473A (zh) 哒嗪类衍生物及其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10818184

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10818184

Country of ref document: EP

Kind code of ref document: A1